Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation

European Respiratory Journal

Volumn 50, Issue 4, 2017, Pages

  Chesov, Dumitru ^a   Ciobanu, Nelly ^b   Lange, Christoph ^c,d,e   Schön, Thomas ^f,g   Heyckendorf, Jan ^c   Crudu, Valeriu ^b  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b Phthisiopneumology Institute   (Moldova)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KALMAR COUNTY HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; KATG PROTEIN; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HUMAN; KATG GENE; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85031697705     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01752-2017     Document Type: Letter

References (10)

1. van Leth F, Guenther G, Hoffmann H, et al. Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201705-0995LE].
2. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Wayne, CLSI, 2011.
3. Schön T, Jureen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786–793.
4. Otto-Knapp R, Vesenbeckh S, Schönfeld N, et al. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. Int J Tuberc Lung Dis 2016; 20: 1275–1278.
5. Kahlmeter G. The 2014 Garrod Lecture: EUCAST–are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427–2439.
6. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464–1473.
7. Wang TY, Lin SM, Shie SS, et al. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 2014; 9: e86316.
8. Chien JY, Chen YT, Wu SG, et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 2015; 21: 59–68.
9. Huyen MNT, Cobelens FGJ, Buu TN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 2013; 57: 3620–3627.
10. Domínguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.